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Abstract
In spite of accelerating human genome discoveries in a wide variety of diseases of public health 
significance, the promise of personalized health care and disease prevention based on genomics 
has lagged behind. In a time of limited resources, public health agencies must continue to focus on 
implementing programs that can improve health and prevent disease now. Nevertheless, public 
health has an important and assertive leadership role in addressing the promise and pitfalls of 
human genomics for population health. Such efforts are needed not only to implement what is 
known in genomics to improve health but also to reduce potential harm and create the 
infrastructure needed to derive health benefits in the future.
Introduction
A decade after the completion of the human genome project, we live in an era of 
unprecedented gene discovery for almost all human diseases.1–3 Discoveries are fueled by 
declining laboratory research costs and multiplexing platforms.4–6 Promise of the impact of 
genomics on health care and disease prevention is being heralded by prominent scientists.7 
In an online horizon scanning of genomic tests, more than 200 new tests were found that are 
in transition from bench to bedside in the past year.8 More than 1800 tests for genetic 
diseases are available9 and an increasing number of genetic conditions are included in 
newborn screening panels.10 However, there is a currently a wide gap between new 
discoveries and the realization of their promise for population health.11 The use of human 
genomics carries the potential for harm, especially from unnecessary or unproven 
interventions.12 The recent surge of direct-to-consumer (DTC) sales of personal genomic 
tests exemplifies the premature deployment of genomic technologies without a scientific 
evidence base.13
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The incorporation of human genomic discoveries into public health practice must deal with 
an apparent paradox. The mission of public health is to improve health from a population 
perspective14 and its unit of intervention is the “population,” an approach seemingly at odds 
with the “one person at a time” vision of genomic medicine.15 The debate about the role of 
genomics in public health practice has been ongoing for quite some time. Some point out 
that that the applications of human genomics will be made at the clinical level and not 
through population screening.16 Some have even argued that there is very little role for 
genomics in public health when the environmental causes of disease are known (i.e., 
infectious, chemical, behavioral, and social factors).17 Moreover, in a time of diminishing 
resources, new technologies can divert much needed resources away from what can be done 
today in delivering basic public health services and addressing social and environmental 
determinants of disease.18 Finally, a reductionist, individually targeted approach to health 
may not substantially improve the health of populations. Such is the dilemma of human 
genomic applications in public health practice.
Increasingly, a public health research agenda is being articulated for the translation of 
human genomic discoveries into health benefits. This includes multiple population 
disciplines such as epidemiology, behavioral, social, and communication sciences.19–22 
These disciplines assess the impact of genomic factors and their interactions with 
environmental and social factors on population health. In addition, the use of genomics in 
public health research is expected to lead to better identification of environmental causes of 
diseases using studies on gene–environment interaction,23 epigenetics,24 and Mendelian 
randomization.25
Nevertheless, traditional public health practice represented by programs at federal, state, 
local, and community levels have not integrated human genomic advances, except in certain 
well-established programs such as newborn screening.26 Most public health practitioners do 
not have the training to integrate rapidly emerging genomic information into their programs, 
although many see future value for using genetic information.27 The contention in this paper 
is that there is a real, current, and increasing role for human genomics in public health 
practice, and a more assertive and broad-based approach to human genomics that takes into 
account multilevel interventions, including policy change, clinical–public health 
partnerships, and consumer and provider education.
Three priorities are discussed for the integration of genomics into public health practice. The 
focus is on human genomics, including both genetic diseases and common diseases with 
strong genetic components, information derived from germline, somatic, and gene products 
such as expression profiles, and proteomics. Not part of this paper are public health issues 
related to genetic engineering of crops and their consequences on people (e.g., safety and 
broader consequences of spread into other parts of the ecosystem); or public health issues 
related to pathogen genomics in developing new diagnostic tests, tracking infectious 
diseases in populations,28 and new vaccines.29
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Multilevel Interventions in Public Health Practice
The Association for State and Territorial Health Officials recently revisited the well-known 
framework of three essential public health functions (assessment, policy development, and 
assurance and evaluation) and 10 essential services for genomics.30 It is not the intent of this 
paper to discuss these functions and services, as in previous publications,19,31 but to expand 
on priorities for short-term action within these services. It is recognized that public health is 
practiced at multiple levels, including federal agencies, state and local health departments, 
and clinical medicine as well as the private sector.14 Generally, national and state public 
health roles tend to differ. States are typically in delivery mode, whereas federal roles are 
more often informational and providing funding, policy, and regulation.
The primary audience of this paper are those in state and local health departments, voluntary 
organizations, and others addressing health-related issues on a population basis. Public 
health uses an array of tools and actions to ensure health and focus more on prevention than 
clinical management.32 Generally, addressing social determinants of health (reduced 
poverty, increased education) can have the largest impact on population health.32 Policy-
level interventions can make the individual’s default decisions healthy (such as policy 
interventions to reduce tobacco use, trans-fats and salt in the diet, clean air, seat belt laws, 
and occupational safety requirements).32 In the context of human genomics, regulatory 
approaches are needed to control misuse and overuse of new technologies.33 The Food and 
Drug Administration (FDA) is currently moving to apply its existing regulatory authorities 
to laboratory-developed tests (LDTs), especially the direct-to-consumer market industry in 
genetic testing.34
Public health interventions also include clinical interventions that require limited contact but 
confer long-term health protection (such as immunizations to prevent the spread of 
infectious diseases and colonoscopy to reduce morbidity from colorectal cancer). Another 
form of public health interventions involves ongoing direct clinical care 
(suchasHIVtreatmenttoreducetransmission,treatmentof hypertension and high cholesterol to 
reduce the risk of heart disease). Public health also includes health education and counseling 
(such as health education about diet and physical activity). Interventions focusing on policy 
contexts tend to have greater health impact than health education, because they reach 
broader segments of society and require less individual effort. Nevertheless, implementing 
interventions at multiple levels can achieve the most public health benefit. For example, the 
successful reduction in the number of folic acid–preventable neural tube defects was 
achieved by interventions using multiple levels. The most effective intervention was FDA’s 
mandated folic acid food fortification efforts, followed by clinical and educational 
interventions to encourage women to include more folic acid in their diet.35,36
How can human genome discoveries fit into public health practice and provide new tools to 
achieve important public health goals? There are currently a few applications for which there 
is potential public health benefit. Family health history and some genetic tests provide 
mechanisms for early detection and intervention for a number of conditions, mostly in 
newborn screening10 and genetic disorders with high individual risk.37–39 Recent evidence, 
for example, suggests that cascade screening of first-degree relatives for selected conditions 
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such as familial hypercholesterolemia (FH), a main cause of premature heart disease38 and 
Lynch syndrome,39 a main cause of early-onset colorectal cancer, can reduce morbidity and 
mortality outcomes in relatives of affected people.
The implementation of such applications could save thousands of lives every year.37–39 
Implementation can be achieved using multiple levels, primarily working with clinicians and 
conducting health education. Policies to enhance the oversight of genomic testing by 
ensuring the use of evidentiary standards of validity and utility as well as quality-testing 
process are crucial.33
Current Priorities for Public Health Practice in Genomics
Table 1 shows three immediate priorities for public health action that are essential to reap the 
population health benefits of emerging human genomic discoveries: (1) serving as the honest 
broker for emerging genomic applications in practice; (2) implementing current evidence-
based genomic applications to improve health and prevent disease, while discouraging 
premature use, misuse, and overuse of genomic applications; and (3) using genomics tools to 
evaluate the health impact of public health interventions regardless of whether they currently 
use genomics. These actions are highly synergistic as shown in Figure 1.
Priority 1: Serving as the Honest Broker for Genomic Applications in Practice
The most important priority for public health practice today in genomics is to be the honest 
broker to inform providers, the public, and policymakers whether the deployment of a 
particular technology for a particular intended use can have a net positive health impact on 
the population.40 Because of the potential for conflicts of interests among various groups, 
public health can serve as an unbiased convener of stakeholders.
Although such a role is not well established in the genomic arena at present, for other areas 
of health care and disease prevention, some precedents exist, for example, the U.S. 
Preventive Services Task Force (USPSTF), which makes evidence-based recommendations 
on clinical practices to improve prevention.41 Similarly, the Community Guide makes 
evidence-based recommendations for community prevention efforts.42 NIH sponsors 
consensus development panels around specific health issues and applications (e.g., the recent 
panel on family history in primary care).43
Newborn screening provides an important model for the integration of genomic modalities 
into the public health sphere. For example, state-specific panels have made 
recommendations on which genetic conditions should be included in the screening panels, 
and because of state-by-state variation, a federal advisory panel now makes nationwide 
recommendations for which conditions to include in newborn screening, incorporating a 
rigorous process for assessing evidence. Such a change will enhance the uniformity and 
evidentiary basis for newborn screening programs.10
In 2005, the CDC launched an independent multidisciplinary panel to address specifically 
the issue of genetic applications in clinical practice and disease prevention 
(www.egappreviews.org/default.htm). The Evaluation of Genomic Applications for Practice 
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and Prevention (EGAPP) working group systematically reviews and updates evidence of 
validity and utility of genomic applications and makes recommendations for appropriate use. 
EGAPP has filled a void in genomic medicine technology assessment. Several 
recommendations have been issued to date and more are under way.
A transparent, independent, and continuously updated assessment of emerging genomic 
applications is crucial to save unnecessary healthcare expenditures from unwarranted tests, 
minimize harm to individuals and groups from the unintended consequences of premature 
use of technologies, and maximize the potential population health benefits of rapidly 
emerging technologies.
The EGAPP working group has established methods for reviewing the evidence for different 
types of genomic tests, including those for screening, early detection, risk assessment and 
prognosis, as well as therapeutic choice (pharmacogenomics). As shown in Table 2, in 
collaboration with the EGAPP working group and various stakeholders, the CDC is 
establishing an evidence-based triaging of emerging genomic applications with a three-tier 
classification schema that would be based on the EGAPP working group methods paper.44 
Tier-1 applications include those with sufficient evidence for validity and clinical utility for 
the test to be implemented into practice (e.g., Lynch syndrome). Tier-2 applications are those 
with sufficient evidence of validity and promising evidence of utility but insufficient to 
support a recommendation for use. For such applications, outcomes research is needed in 
clinical trials and/or comparative effectiveness studies. In addition, public health and clinical 
practitioners can provide individuals with information needed for them to make informed 
decisions on use. Tier-3 applications are those with either sufficient evidence for a lack of 
utility or overt harm, or insufficient evidence on validity and utility. Public health would 
discourage using Tier-3 applications until further studies establish validity and utility (e.g., 
personal genomic tests sold directly to consumers).
Evidence-based triaging of genomic applications would be an iterative process, constantly 
changing based on newly acquired evidence.45,46 Finally, it is important to conduct cost-
effectiveness analyses as part of this priority to assess the preventable burden and associated 
costs as a potential guide for implementation. This was recently done for Lynch syndrome 
cascade screening.47
Priority 2: Implementing Evidence-Based Genomic Applications and Discouraging 
Premature Use of Unvalidated Applications
In addition to being an honest broker, there are important roles for public health programs 
(Table 2). For Tier-1 applications, exemplified by Lynch syndrome, public health programs 
can actively encourage implementation of evidence recommendations. For Tier-2 genomic 
applications, exemplified by the use of family history as a tool for risk assessment and 
disease prevention (see below), public health programs can promote additional data 
collection on health impact to assess the added value of using genomic tools in practice. For 
Tier-3 genomic applications, such as DTC personal genomics tests, public health programs 
can actively discourage their use while additional research is done.
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Public health actions can operate at multiple levels, as discussed earlier, for example, by 
developing health education campaigns targeted to at-risk individuals, clinicians, 
policymakers, and payers. Implementation could also be integrated into various disease-
specific or categoric public health programs. As noted earlier, there are also genomic 
applications for which organized efforts of public health programs, namely, newborn 
screening, represent the largest public health genetics program today. It remains to be seen 
whether or not an expansion of such a program to other conditions outside the newborn 
period is warranted, but the general principles of evidence assessment set a worthy precedent 
for the process of determining the desirability of expansion.
The example of Lynch syndrome discussed in Table 2 illustrates another form of screening 
in a different setting and life stage (i.e., screening all newly diagnosed cases of colorectal 
cancer for Lynch syndrome). It clearly shows the challenges that public health faces in 
implementing such evidence-based applications population-wide. At a time when half of 
adults do not get colorectal cancer screening, one may wonder whether or not state public 
health cancer programs should emphasize the small proportion of colorectal cancer that have 
Lynch syndrome or would this be best left to the clinical care system alone? In a CDC multi-
disciplinary workshop held in September 2010 to discuss the implementation of EGAPP 
Lynch syndrome recommendations, data were presented that currently less than 10% of 
cases of Lynch syndrome are ascertained by the healthcare system, and several stakeholders 
asserted that public health should take on the responsibility for ensuring that effective Lynch 
syndrome services are delivered and tracked using approaches embedded in state cancer 
registries.
Many challenges remain to make this first example of cascade screening a reality in public 
health practice. Other examples could follow, including familial hypercholesterolemia, 
hereditary breast/ovarian cancer, and others, affecting larger and larger segments of the 
population. Prioritization will obviously depend on level of evidence, the burden of 
morbidity and mortality that can be prevented in the population, and cost effectiveness of 
interventions. Finally, public health can use family history to reach relatives of individuals 
with common diseases and to implement nongenetic evidence-based recommendations (such 
as screenings and primary prevention in diabetes, cancer, and heart disease), therefore 
achieving larger health impact than by targeting genetic conditions alone.
Priority 3: Using Population Data to Guide Implementation of Genomic Applications and to 
Evaluate the Impact of Interventions That Currently Do Not Use Genomics
One important public health function is surveillance and epidemiology that provide “data for 
action” to guide implementation and evaluation of the impact of interventions. Examples 
include population-based disease registries,48,49 surveys of risk factors,50 and vaccine 
adverse effects.51 The challenge is to assess implementation (e.g., use of genomic tests), the 
appropriateness of implementation (e.g., in comparison with recommended use), health 
outcomes, as well as disparities in use and outcomes.52
In addition, human genomics may enhance surveillance and epidemiology assessments of 
existing or planned public health interventions that are not genome-based. Current 
population-level approaches to prevention have not been fully realized. For example, most 
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Americans do not get enough physical activity, an increasing proportion is overweight, and 
many do not adhere to evidence-based screening recommendations (such as colorectal 
cancer screening). Could family history or genomic information be used to identify subsets 
of the population that merit more (or less) intensive or different types of interventions?
For example, family health history can be used as a stratifying tool for measuring health 
impact in surveillance systems. Family history is a simple and inexpensive application 
available in clinical practice today.53 Family history reflects not only genetics but also 
environmental and socioeconomic factors. Furthermore, clinical decisions that can readily be 
made on the basis of such history have little or nothing to gain by expensive genomic 
testing. Family history is a risk factor for most diseases of public health significance, 
especially common chronic diseases. Only occasionally does family history of a condition 
point to a classical genetic disorder. Most often, the presence of a family history reflects 
unmeasured genetic and environmental effects and is an indicator of higher risk for the same 
disease in comparison with the average population risk.53
Although there has been considerable debate as to whether family history can prevent 
common disease, it can be used as a surveillance tool to examine the impact of population-
level interventions. For example, population-based family studies in Utah have shown that 
14% of Utah families have a positive family history of coronary heart disease; these families 
account for 72% of early coronary events (aged <50 years) and 48% of coronary heart 
disease events at any age.54 Such data suggest that the implementation of family-centered 
interventions could lead to overall population health benefits. A recent evaluation of a Utah 
nationwide program to identify familial hyper-cholesterolemia patients showed that 
participants in the treatment program achieved greater cholesterol reductions than the 
comparison group.55
Another condition where family history may play a role is diabetes. Given the large number 
of undiagnosed diabetics, and the proven effectiveness of primary prevention measures 
(physical activity and medications), it is important to assess all approaches to help find 
undiagnosed diabetics and prediabetes. A recent analysis56 of the National Health and 
Nutrition Examination Survey (NHANES; see description below) found that by adding 
family history to risk prediction analysis of undiagnosed cases, more than 600,000 such 
cases are projected to be found in the U.S. population. Although early intervention among 
people with prediabetes can delay progression to diabetes, the effectiveness of population 
screening to identify people at risk has not been completely resolved. Such population data 
can provide a scientific foundation for extending evidence-based recommendation for 
screening for diabetes in the U.S. Because of the large number of diabetics in the U.S., a 
family-based intervention to target their relatives for primary prevention and early detection 
could have a substantially large impact on disease burden compared to screening programs 
for rare genetic conditions.
Genomic tools are increasingly available to evaluate the health impact of interventions on 
different segments of the population. For example, genomics could be used as a means to 
help target specific environmental and occupational exposures by setting the maximum 
allowed exposure levels based on the most susceptible people in the population.57,58 The 
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declining costs of genomewide analysis are allowing us to add multiple genetic variations to 
existing surveillance systems for population health.
The NHANES is such an example at the national level.59 The CDC and others have 
measured an increasing number of genetic variants for numerous diseases to this uniquely 
representative, large, population-based survey of the U.S. population.60 This survey 
evaluates the health status of various ethnic/racial subgroups; to monitor the impact of 
different interventions (e.g., removing lead from the gasoline resulting in dramatic drop in 
serum lead levels in the U.S.)61; and generate data to inform health policies and 
interventions. More than 10,000 health-related variables are available in NHANES, 
including clinical, physiologic, risk factor, biochemical, and epidemiologic data.
The addition of hundreds of genetic variants to this survey is allowing public health 
epidemiologists to assess the potential added value of genetic information on the health 
impact of public health interventions. Building on the folic acid story mentioned above is 
one example. A genetic variant in the MTHFR gene (TT variant), affecting 5% of the 
population, was found to be associated with a thermolabile enzyme, leading to a relative 
functional deficiency in folic acid, a known risk factor for neural tube defects.62 An 
important question is whether or not the effectiveness of folate supplementation extends to 
this subgroup of the population. Using NHANES analyses, one study63 recently estimated 
that the current RDC allowance of folic acid (400 μg/day) should be adequate for individuals 
with the TT genotype. Another study,64 also using NHANES data, showed that folic acid 
supplementation increased folate levels among all studied alleles of the MTHFR gene, 
confirming current policies for folic acid supplementation.
Genomic analyses can be readily extended to the evaluation of many public health 
interventions (such as salt reduction, smoking campaigns, fat reduction, control of drug or 
vaccine side effects) on health outcomes and indicators in subsets of the population. Such 
analyses are not merely of academic interest but could inform us whether population 
interventions (including prevention or therapeutic interventions) need to be adjusted to reach 
the most susceptible in the U.S. population, which may include testing individuals before an 
intervention or designing a population strategy that addresses the most vulnerable segments 
of the population. Similar epidemiologic analyses can be done to explore potentially harmful 
effects of interventions in subgroups of the population (e.g., vaccine or drug side effects) and 
protection from harm of environmental and occupational exposures.
Conclusion
Three immediate priorities for action in human genomics are presented that can be 
integrated into model public health programs using multilevel interventions. The 
implementation of these priorities can have both near-term and long-term effects in realizing 
the promise and addressing the limits of human genomic discoveries in population health. 
Albeit small, the current health impact of genomics is likely to increase considerably over 
time as more applications become ready for implementation. Importantly, with minimal 
resources, public health programs can today serve an important honest broker role and use 
their convening function to accelerate progress, minimize potential harm and reduce 
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unnecessary health-care costs, while setting a strong scientific and ethical foundation based 
on population-specific data, for future applications of genomics. The balanced approach 
presented here requires minimal investment compared to the massive investment in basic 
genomic sciences and technologies, and need not take away precious resources from public 
health programs in implementing current interventions that can reduce the burden of illness 
and death from diseases of public health significance.
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Table 1
Current priorities for public health practice to address human genomic information to improve population 
health
Priorities Actions Magnitude and timeline of population health 
impact
Serving as the honest broker for 
emerging genomic applications to 
consumers, providers, and policymakers
Conducting and sponsoring knowledge 
synthesis and evidence recommendations on 
appropriate use (see examples in Table 2)
Small but increasing impact in saving unnecessary 
healthcare costs and preventing harm while 
illuminating what is ready for implementation
Implementing evidence-based genomic 
applications and discouraging use of 
unvalidated applications
Implementing multilevel interventions (see 
examples in Table 2)
Small but increasing impact for improving health 
and reducing unnecessary healthcare costs
Evaluating impact of public health 
interventions that currently do not use 
genomics (e.g., smoking cessation)
Evaluating benefits and harm of public 
health programs in subgroups of population 
using genomic tools
Small but increasing impact in evaluating current 
public health programs and informing next 
generation of programs
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Table 2
Examples of evidence-based triaging of human genomic applications and integration into public health 
programs using multilevel interventions
Evidence-based triaging




implementation Established validity/promising utility
Unclear benefits and 
harm; or evidence 
recommendation against 
use
Examples Lynch syndrome Family history for risk assessment in primary care Personal genomic tests sold 
directly to consumers
Public health issues 3%–5% of all cases of 
colorectal cancer are due to 
this genetic disorder. 
Cancer has early age of 
onset
Family history is a risk factor for common chronic 
diseases. It can be used to target public health 
messages (diet, physical activity, screening)
Several companies selling 
to the public personal 
genomic test to inform 
consumers about risks for 
common diseases
Evidence recommendation EGAPP working group 
recommended in 2009 that 
all new cases of colorectal 
cancer be screened for 
Lynch syndrome. Cascade 
testing of relatives can 
reduce mortality from 
colorectal cancer39
NIH conference in 2009 concluded that while 
“Family history interventions can motivate 
behavior change, the data are not sufficiently 
robust to conclude that routine family history can 
lead to improved health outcomes”a
CDC–NIH conference in 
2009 concluded that there 
is insufficient evidence on 
clinical validity and utility 
of these tests13
Public health actions Promote implementation in 
practice by educating 
providers and patients; 
setting screening programs, 
and developing clinical 




Provide information for decision making about 
family history as disease risk factor; educating 
providers and consumers
Discourage use in practice 
by educating consumers, 
providers, and 
policymakers
Public health surveillance 
and epidemiology
Measure impact of actions 
on implementation and 
outcomes
Measure impact of information on use and 
outcomes
Measure impact of 
discouraging 
implementation on use and 
outcomes
Assess added value in public health interventions 
that do not use genomics to inform future public 
health actions
Assess added value in 
public health interventions 
that do not use genomics to 
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